Zobrazeno 1 - 10
of 110
pro vyhledávání: '"E. Sporn"'
Autor:
E. Sporn, Sinda Bigenzahn, Ursula Pluschnig, Peter Dubsky, Andrea Dal Borgo, Guenther G. Steger, Sebastian F. Schoppmann, Raimund Jakesz, Florian Fitzal, Peter Blaha, Michael Gnant, Thomas Bachleitner-Hofmann, Ruth Exner, O. Riedl, Peter Panhofer
Publikováno v:
Breast Care. 4:155-161
Endocrine therapy has become a key part in the adjuvant treatment of hormone responsive breast cancer. The positive effect on relapse risk reduction is well defined, but therapy is not free from bothersome side effects for which estrogen deprivation
Autor:
Manfred Prager, T. Hoblaj, M. Ploner, Ihor Huk, Peter Polterauer, K. Kubin, E. Sporn, H. J. Böhmig, J. Nanobashvili
Publikováno v:
European Surgery. 40:66-71
BACKGROUND: In this long-term follow-up of a prospective randomized multicentric trial, warp-knitted gelatin-coated double-velour Dacron (GEL-D), warp-knitted collage-coated double-velour Dacron (COL-D) and stretch PTFE bifurcation grafts implanted i
Autor:
Susanne Taucher, Martina Mittlböck, Florian Fitzal, O. Riedl, Raimund Jakesz, Margaretha Rudas, E. Sporn, Thomas H. Helbich, W. Draxler, Michael Gnant
Publikováno v:
Breast Cancer Research and Treatment. 97:9-15
Several case reports and clinical studies in the literature demonstrate needle track seeding after core needle biopsy in patients with breast cancer in up to 50% of cases. The impact of this observation on local recurrence and overall survival rate i
Autor:
Margaretha Rudas, Sebastian F. Schoppmann, Helene Wiener, S. Roka, Peter Birner, Peter Dubsky, Daniela Kandioler, Michael Gnant, Peter Blaha, Thomas Bachleitner-Hofmann, Florian Fitzal, E. Sporn, Raimund Jakesz, Peter Panhofer
Publikováno v:
Breast Care. 1:391-394
Summary Background: Phyllodes tumors are fibroepithelial neoplasms that are extremely rare, comprising less than 1% of all breast neoplasms. Malignant transformation may occur, usually within the stromal component of the phyllodes tumor. The most com
Autor:
W. Draxler, Günther G. Steger, S. Roka, Catharina Wenzel, Daniela Kandioler, Michael Gnant, S. Taucher, Margarethe Rudas, Martina Mittlböck, E. Sporn, Raimund Jakesz, P. Dubsky, T. Bachleitner, Florian Fitzal
Publikováno v:
Scopus-Elsevier
BACKGROUND: The benefit of preoperative chemotherapy on outcome in breast cancer has been shown to be highest in patients with complete pathological response (pCR). The objective of this analysis was to determine the predictive value of progesterone
Publikováno v:
European Surgery-Acta Chirurgica Austriaca. 34:127-130
Background: Peroxisome proliferator-activated receptor-γ (PPARγ) ligands were shown to induce the vascular endothelial growth factor (VEGF) synthesis in several cell types. We tested the effect of ciglitazone, one of the most specific PPARγ agonis
Autor:
Peter Polterauer, A. Fuegl, E. Sporn, I. Huk, Tadeusz Malinski, M. Prager, C. Neumayer, J. Nanobashvili
Publikováno v:
European Surgery-Acta Chirurgica Austriaca. 34:83-89
Background: Any surgical manoeuvre that involves cessation of blood supply to an organ with subsequent re-establishment of blood flow can result in ischaemia/reperfusion (I/R) injury. The consequences of such injury are local and remote tissue destru
Autor:
Ferdinand Mühlbacher, Susanne Rockenschaub, Thomas Windhager, Thomas Soliman, Herwig Pokorny, E. Sporn, Rudolf Steininger, Gabriela A. Berlakovich, Felix B. Langer, Edith Freundorfer
Publikováno v:
Transplant International. 13:129-135
In recent years, alcoholic cirrhosis has been accepted as an indication for OLT, compliance of patients suffering from alcoholic cirrhosis is still under discussion, however. 118 patients who had undergone OLT for alcoholic cirrhosis were considered
Publikováno v:
Zeitschrift für Gastroenterologie. 51
Autor:
Peter Panhofer, Florian Fitzal, Peter Dubsky, Raimund Jakesz, Sinda Bigenzahn, Andrea Dal Borgo, Ruth Exner, E. Sporn, Guenther G. Steger, Peter Blaha, Michael Gnant
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 1 (2009)
Recent advances in the treatment of early breast cancer have improved clinical outcomes and prolonged survival, especially in women with endocrine-responsive disease. However, cancer therapies including cytotoxic chemotherapy, ovarian suppression, an